Dateline City:
WHITEHOUSE STATION, N.J.
-Merck Expands Lambrolizumab Clinical Development Program-
-Study Published Online in the New England Journal of Medicine-
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced the presentation of preliminary results from an ongoing
Phase IB expansion study evaluating the safety and efficacy of
lambrolizumab (MK-3475), Mercks investigational antibody therapy
targeting PD-1, in patients with advanced (inoperable and metastatic)
melanoma.
Language:
English
Contact HTML:
MerckMedia Contacts:Ian McConnell, 973-901-5722Cathy Cantone, 908-327-3013orInvestor Contacts:Carol Ferguson, 908-500-1101Justin Holko, 609-915-8293
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more